Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.24
+3.2%
$2.22
$1.63
$4.66
$11.60M0.82262,822 shs38,157 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.41
+4.5%
$0.37
$0.22
$4.79
$17.02M-0.23837,821 shs365,914 shs
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
$0.73
$0.93
$2.22
$13.10
$3.75MN/A108,185 shs22,784 shs
Upexi, Inc. stock logo
UPXI
Upexi
$11.99
+7.0%
$8.73
$1.90
$22.57
$425.03M-0.3867,853 shs542,106 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
+3.23%-0.88%-21.40%-12.84%-39.78%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
+4.48%+14.53%+22.57%-1.30%-81.67%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
0.00%0.00%0.00%0.00%-87.15%
Upexi, Inc. stock logo
UPXI
Upexi
+6.96%+5.36%+21.48%+339.19%+22.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCardia, Inc. stock logo
BCDA
BioCardia
3.5016 of 5 stars
3.85.00.00.00.02.50.6
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.5531 of 5 stars
3.14.00.00.02.80.01.3
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
1.565 of 5 stars
0.05.00.00.02.33.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,016.07% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.25
Hold$4.921,097.43% Upside
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
0.00
N/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RWOD, LPTX, UPXI, and BCDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K3,866.24N/AN/A($1.11) per share-2.02
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$2.35 per shareN/A
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
$16.56M27.45N/AN/A$2.85 per share4.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$81.41M-$1.70N/AN/AN/AN/A-116.24%-93.18%8/11/2025 (Estimated)
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
-$23.66MN/A0.00N/AN/AN/AN/A7/8/2025 (Estimated)

Latest RWOD, LPTX, UPXI, and BCDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/2025Q1 2025
Upexi, Inc. stock logo
UPXI
Upexi
N/A-$2.87N/A-$2.87N/A$3.16 million
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
3/26/2025Q4 2024
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million
3/26/2025Q4 2024
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.39-$0.37+$0.02-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
1.78
1.78
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
3.97
3.97
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
0.35
0.58
0.53

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
20.07%
Upexi, Inc. stock logo
UPXI
Upexi
5.68%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
2.00%
Upexi, Inc. stock logo
UPXI
Upexi
31.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.18 million3.67 millionOptionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million36.25 millionOptionable
Redwoods Acquisition Corp. stock logo
RWOD
Redwoods Acquisition
N/A5.17 million5.06 millionNot Optionable
Upexi, Inc. stock logo
UPXI
Upexi
13037.92 million863,000Optionable

Recent News About These Companies

Upexi Joins Webull Corporate Connect Service Platform
Upexi options begin trading on Nasdaq market
Upexi Approved for Options Trading on Nasdaq
Upexi (NASDAQ:UPXI) Raised to Hold at Wall Street Zen
Upexi Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.24 +0.07 (+3.23%)
Closing price 06/9/2025 03:59 PM Eastern
Extended Trading
$2.23 -0.01 (-0.45%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.41 +0.02 (+4.48%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$0.41 +0.00 (+0.58%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Redwoods Acquisition stock logo

Redwoods Acquisition NASDAQ:RWOD

Redwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York.

Upexi stock logo

Upexi NASDAQ:UPXI

$11.99 +0.78 (+6.96%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$12.00 +0.01 (+0.08%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.